Skip to main content
Clinical Trials/NL-OMON56339
NL-OMON56339
Not Yet Recruiting
N/A

Assessment of myocardial function, endothelial function and perFUSION in early and advanced disease stages of Hypertrophic CardioMyopathy: FUSION-HCM - FUSION-HCM

Amsterdam UMC0 sites100 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Amsterdam UMC
Enrollment
100
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • MYBPC3 mutation carrier
  • MYH7 mutation carrier
  • Genotype\-negative first degree relative of a MYBPC3 or MYH7 mutation carrier

Exclusion Criteria

  • \>\=70 years old
  • Insulin\-dependent diabetes mellitus
  • Claustrophobia
  • Pacemaker/ICD
  • Renal insufficiency \<30 GFR
  • Hypertension (systolic \>140mmHg or diastolic \>90mmHg)
  • For the genotype negative group, no phenotype group, and mild phenotype group:
  • the use of blood pressure medication (diuretics, beta\-blockers, ACE\-inhibitors,
  • angiotensin II receptor blockers, calcium channel blockers, alpha blockers)
  • For the HCM phenotype group: when it is unsafe to withhold from blood pressure

Outcomes

Primary Outcomes

Not specified

Similar Trials